Rx Sampling In "Spotlight" Of Boston Grand Jury As Part Of TAP Investigation
Executive Summary
Pharmaceutical companies should consider how their sampling programs will look in "the very bright spotlight of a federal grand jury investigation," Boston Assistant U.S. Attorney Michael Loucks said during the Food & Drug Law Institute annual meeting April 19 in Washington, D.C.
You may also be interested in...
PBM Subpoenas Piling Up; AdvancePCS Notes Firms Are Good Source Of Data
The Boston U.S. Attorney's Office subpoenas to pharmacy benefit managers reflect the position of PBMs as the best source of data on pharmaceutical use and pricing, AdvancePCS said
PBM Subpoenas Piling Up; AdvancePCS Notes Firms Are Good Source Of Data
The Boston U.S. Attorney's Office subpoenas to pharmacy benefit managers reflect the position of PBMs as the best source of data on pharmaceutical use and pricing, AdvancePCS said
TAP Lupron Sales Execs Plead Not Guilty; Pre-Trial Work Begins
The criminal case against one current and five former TAP sales executives is expected to complete the pre-trial phase by spring 2002.